TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18997198

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg per day)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Nonaspirin group
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2539
Study: 16227633

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: 5‐FU/LV and interferon Alfa‐2a (IFNA‐2a)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: 5‐FU/LV and pelvic chemoradiotherapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: Pelvic chemoradiotherapy alone
Number of subjects: 499
Study: 12825781

Group type: EXPERIMENTAL
Intervention: Regulation group (self-testing techniques)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strategy-control group (standard strategies only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 10227571

Group type: EXPERIMENTAL
Intervention: Relapsers (n = 26)
Number of subjects: 51
Study: 8688340

Group type: EXPERIMENTAL
Intervention: Continuous tamoxifen therapy beyond 5 years
Number of subjects: 342

Group type: COMPARATOR
Intervention: Stopping tamoxifen at 5 years
Number of subjects: 342
Study: 1884668

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 6342456

Group type: EXPERIMENTAL
Intervention: Preventive measures (study group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 31932939

Group type: EXPERIMENTAL
Intervention: Hemovac drain
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Deep breathing technique
Number of subjects: 114

Group type: COMPARATOR
Intervention: Non-drain group (control)
Number of subjects: 114
Study: 30945169

Group type: EXPERIMENTAL
Intervention: Advance expectations regarding the (ir) relevant stimuli formed in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No concrete advance expectations formed in Experiment 2
Number of subjects: 0
Study: 28234590

Group type: EXPERIMENTAL
Intervention: Experimental group (received radiographs only when clinically indicated)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (received screening radiographs immediately after fixation and at 2 weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 25787998

Group type: EXPERIMENTAL
Intervention: United Kingdom dietary guidelines
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (traditional British diet)
Number of subjects: 165
Study: 23512339

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 20944071

Group type: EXPERIMENTAL
Intervention: Methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation patterns in myeloma stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation patterns at the transition from myeloma to plasma cell leukemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation variability within presentation myeloma samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation subgroups defined by translocations and hyperdiploidy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperdiploid samples identified by unsupervised clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA methylation changes during disease progression
Number of subjects: 0
Study: 19170853

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle changes (detailed advice on reducing body weight, improving diet quality, and increasing physical activity)
Number of subjects: 209

Group type: COMPARATOR
Intervention: General information about healthy food choices and guidance on increasing physical activity (control group)
Number of subjects: 209
Study: 17558069

Group type: EXPERIMENTAL
Intervention: Enteral glutamine 45 g/day for 5 days in addition to standard care (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care alone (group B)
Number of subjects: 120
Study: 15284957

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 88
Study: 11093454

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain intensity ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of tender points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total tender point pain intensity score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall responsiveness of measures
Number of subjects: 0
Study: 8801694

Group type: EXPERIMENTAL
Intervention: Stroke unit treatment
Number of subjects: 1241
Study: 1505614

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg tid for 6 days (young subjects)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg tid for 6 days (elderly subjects)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Compliance measurement (both groups)
Number of subjects: 24
Study: 6377973

Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metoclopramide (Group 2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and in the morning (Group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and metoclopramide in the morning (Group 4)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cimetidine and metoclopramide in the morning (Group 5)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and metoclopramide and cimetidine in the morning (Group 6)
Number of subjects: 150
Study: 29447832

Group type: EXPERIMENTAL
Intervention: Intervention with grandmothers involved
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group without grandmothers
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Intervention with teenagers only
Number of subjects: 323
Study: 29408567

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) group (HIITG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HIITG
Number of subjects: 16
Study: 1427426

Group type: EXPERIMENTAL
Intervention: Human recombinant alpha-IFN (Roferon-A)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Conventional chemotherapy (hydroxyurea)
Number of subjects: 322
Study: 22289904

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg body weight) 4 hours before cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Natrium chloride
Number of subjects: 20
Study: 20398394

Group type: EXPERIMENTAL
Intervention: Hippotherapy simulator with rhythmic movement
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hippotherapy simulator without rhythmic movement
Number of subjects: 37
Study: 18547839

Group type: EXPERIMENTAL
Intervention: Closed-eruption exposure
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Open-eruption exposure
Number of subjects: 32
Study: 15929755

Group type: EXPERIMENTAL
Intervention: Eradication group (received standard antibiotic therapy for H. pylori)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-eradication group (no treatment for H. pylori)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eradication group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Responders (those who achieved complete or partial response)
Number of subjects: 36
Study: 12628815

Group type: EXPERIMENTAL
Intervention: Single dose (3.3 microg) of TBE vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (unvaccinated or vaccinated with basic immunisation and regular boosters)
Number of subjects: 30
Study: 10656156

Group type: EXPERIMENTAL
Intervention: Group treatment based on psychosomatic and physio-therapeutical principles, cognitive and operant behavioral therapy, 2.5 hours per week for 10 weeks.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 53
Study: 8689162

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 10
Study: 1794298

Group type: EXPERIMENTAL
Intervention: Levodropropizine (60 mg active drug, oral drops, 12 h and 1 h before bronchoscopy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levodropropizine
Number of subjects: 16
Study: 6610161

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31471244

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination topical benzoyl peroxide and clindamycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 12
Study: 29102362

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1200
Study: 28283134

Group type: EXPERIMENTAL
Intervention: Simple Chest Camp (SCC)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Infotainment Chest Camp (ICC)
Number of subjects: 318
Study: 24845578

Group type: EXPERIMENTAL
Intervention: 12-hr interim test
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 2-hr interim test
Number of subjects: 106

Group type: COMPARATOR
Intervention: No interim retrieval experience
Number of subjects: 106
Study: 22481427

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine containing 3.75 μg A/H1N1 antigen
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine containing 7.5 μg A/H1N1 antigen
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted vaccine containing 15 μg A/H1N1 antigen
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted formulations
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 654
Study: 20451184

Group type: EXPERIMENTAL
Intervention: GDF‐9 c.G546A polymorphism
Number of subjects: 106

Group type: COMPARATOR
Intervention: GDF‐9 c.G169A polymorphism
Number of subjects: 106

Group type: COMPARATOR
Intervention: GDF‐9 c.C447T polymorphism
Number of subjects: 106
Study: 17666715

Group type: EXPERIMENTAL
Intervention: Group A: Infusion of 0.025 to 0.1 microg x kg(‐1) x min(‐1) with a PCA bolus of 0.25 microg x kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group B: Infusion of 0.025 microg x kg(‐1) x min(‐1) with a PCA bolus increased from 0.25 to 1 microg x kg(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 18407883

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diversified Placement Approach (DPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPA
Number of subjects: 0
Study: 15469647

Group type: EXPERIMENTAL
Intervention: Probiotic (6.5 x 10(9) Lactobacillus casei Shirota cells twice daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prebiotic (lactulose 10 g twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11216978

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9284505

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8451502

Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3511127

Group type: EXPERIMENTAL
Intervention: Cromolyn-like agent administered via a Nebulizer Chronolog, used four times a day for 12 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cromolyn-like agent
Number of subjects: 19
Study: 11575289

Group type: EXPERIMENTAL
Intervention: Computerized reminders
Number of subjects: 6371

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 6371
Study: 31310464

Group type: EXPERIMENTAL
Intervention: HTK cardioplegic solution (Custodiol®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent hypothermic blood solution
Number of subjects: 50
Study: 28927731

Group type: EXPERIMENTAL
Intervention: Coated contact lenses
Number of subjects: 19

Group type: COMPARATOR
Intervention: Uncoated contact lenses
Number of subjects: 19
Study: 28051838

Group type: EXPERIMENTAL
Intervention: MAS‐XR (mixed amphetamine salts) 60 mg and 80 mg combined
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 24613817

Group type: EXPERIMENTAL
Intervention: Intensive care with redeemed antihypertensive treatment
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Screen-detection and early treatment onset
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Change in cardiovascular risk factors (HbA1c, cholesterol, blood pressure, BMI)
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Meeting treatment targets for HbA1c, cholesterol, and blood pressure
Number of subjects: 1533
Study: 22713093

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Health Education
Number of subjects: 255

Group type: COMPARATOR
Intervention: Brief Advice
Number of subjects: 255
Study: 19801386

Group type: EXPERIMENTAL
Intervention: PECO with hypercapnia
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PECO while breathing room air
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rest with hypercapnia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rest while breathing room air
Number of subjects: 11
Study: 18040531

Group type: EXPERIMENTAL
Intervention: Various interventions listed in the abstract
Number of subjects: 0
Study: 16190797

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 12079440

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (statins and fibrates)
Number of subjects: 2856

Group type: EXPERIMENTAL
Intervention: Discontinuation of all prior lipid-lowering medications
Number of subjects: 2856

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2856
Study: 10090490

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 200 microg per vaginum q 12 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Concentrated oxytocin plus low-dose vaginal prostaglandin E2 (10 mg q 6 h)
Number of subjects: 30
Study: 7788255

Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl) 20 mg twice daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oxybutynin (Oxy) 5 mg three times daily
Number of subjects: 95
Study: 2138953

Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-nickel diet
Number of subjects: 24
Study: 350506

Group type: EXPERIMENTAL
Intervention: New cream vehicle for flurandrenolide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous formulation
Number of subjects: 0
Study: 30764651

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 203

Group type: COMPARATOR
Intervention: No decision aid (control group)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention preference
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery preference
Number of subjects: 203
Study: 30390639

Group type: EXPERIMENTAL
Intervention: Music intervention via loudspeakers from self-selected genres
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard treatment without music (Control)
Number of subjects: 304
Study: 27058405

Group type: EXPERIMENTAL
Intervention: Enriched environmental activities programme
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual ward activity
Number of subjects: 103
Study: 24675014

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Liberal transfusion threshold
Number of subjects: 2000
Study: 22318191

Group type: EXPERIMENTAL
Intervention: 20-mg long-acting methylphenidate
Number of subjects: 21
Study: 20973316

Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g as slurry with 250 ml of water)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (250 mL of water)
Number of subjects: 12
Study: 17722615

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg/day
Number of subjects: 55
Study: 15692125

Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg/d
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 12829593

Group type: EXPERIMENTAL
Intervention: +4 and +18 (in children younger than 10 years)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: High-risk group (boys older than 9 years, boys aged 1-9 years without +18, girls older than 9 years without +18)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Girls aged 1-9 years with +18
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Age, sex, +4, +18 (independent indicators from multivariate analysis)
Number of subjects: 700
Study: 10736978

Group type: EXPERIMENTAL
Intervention: Heparin and ATIII (Group A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Heparin plus placebo (Group B)
Number of subjects: 2
Study: 8859935

Group type: EXPERIMENTAL
Intervention: enalapril 2.5 mg p.o. + placebo i.v. (day 1) and enalapril 2.5 mg p.o. (day 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: perindopril 2 mg orally (p.o.) + placebo intravenously (i.v.) (day 1) and perindopril 2 mg p.o. (day 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo p.o. + perindopril at 0.167 mg i.v. (day 1) and perindopril 2 mg p.o. (day 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo p.o. + placebo i.v. (day 1) and placebo p.o. (day 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: enalapril 2.5 mg p.o.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: perindopril 2 mg p.o.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: enalapril therapy
Number of subjects: 48
Study: 1509399

Group type: EXPERIMENTAL
Intervention: Liquid crystal contact thermography (LCCT)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Measurement of plasma D-dimer (DD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Bilateral ascending phlebography
Number of subjects: 194
Study: 6362110

Group type: EXPERIMENTAL
Intervention: Trabeculectomy as the primary form of treatment (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional management using medical therapy followed by trabeculectomy only in unsuccessful cases (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (Group B)
Number of subjects: 40
Study: 30403772

Group type: EXPERIMENTAL
Intervention: Walking breaks (5 minutes of self-paced light walking every 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standing breaks (5 minutes of standing every 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prolonged sitting (continuous sitting for 7.5 hours)
Number of subjects: 60
Study: 29941019

Group type: EXPERIMENTAL
Intervention: Sub-sensory sacral neuromodulation (SNM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: SHAM stimulation
Number of subjects: 90
Study: 26728982

Group type: EXPERIMENTAL
Intervention: High-dose Shaoyao Shujin tablet
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Low-dose Shaoyao Shujin tablet
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 276
Study: 24501370

Group type: EXPERIMENTAL
Intervention: Gray matter volume in the hippocampus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gray matter volume in the dorsolateral prefrontal cortex
Number of subjects: 0
Study: 22295811

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Nimodipine (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nimodipine alone (Group B)
Number of subjects: 100
Study: 20929121

Group type: EXPERIMENTAL
Intervention: Shenqi Guchong Recipe (SGR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Kunning Oral Liquid (Control)
Number of subjects: 78
Study: 18037734

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10‐20 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 16118591

Group type: EXPERIMENTAL
Intervention: Pedometer (PED)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Minutes (MIN)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 85
Study: 12384805

Group type: EXPERIMENTAL
Intervention: TIL plus interleukin‐2 (IL‐2) for 2 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: IL‐2 only
Number of subjects: 88
Study: 9507965

Group type: EXPERIMENTAL
Intervention: Reach-to-grasp movements involving living-thing pairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reach-to-grasp movements involving non-living things
Number of subjects: 0
Study: 7921394

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser vaporization of endometriosis
Number of subjects: 44

Group type: COMPARATOR
Intervention: No carbon dioxide laser vaporization of endometriosis (Control)
Number of subjects: 44
Study: 3041818

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 125
Study: 30971205

Group type: EXPERIMENTAL
Intervention: EXCELS-website (mobile-optimized technology platform)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: EXCELS-health coaching
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: EXCELS-website and health coaching
Number of subjects: 480

Group type: COMPARATOR
Intervention: Print booklet
Number of subjects: 480
Study: 30121876

Group type: EXPERIMENTAL
Intervention: 14-week parenting intervention
Number of subjects: 270